BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26073569)

  • 1. 17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management.
    Lee J; Smith D; Rabin N; Tobias J; Yong K
    Hematol Oncol; 2016 Sep; 34(3):165-70. PubMed ID: 26073569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
    El-Ghammaz AM; Abdelwahed E
    Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
    Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
    Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
    Neben K; Lokhorst HM; Jauch A; Bertsch U; Hielscher T; van der Holt B; Salwender H; Blau IW; Weisel K; Pfreundschuh M; Scheid C; Dührsen U; Lindemann W; Schmidt-Wolf IG; Peter N; Teschendorf C; Martin H; Haenel M; Derigs HG; Raab MS; Ho AD; van de Velde H; Hose D; Sonneveld P; Goldschmidt H
    Blood; 2012 Jan; 119(4):940-8. PubMed ID: 22160383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
    Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation.
    Vaxman I; Visram A; Kapoor P; Kumar S; Dispenzieri A; Buadi F; Dingli D; Muchtar E; Gonsalves W; Rajkumar V; Kourelis T; Warsame R; Lacy M; Gertz MA
    Am J Hematol; 2021 Jan; 96(1):E35-E38. PubMed ID: 33068019
    [No Abstract]   [Full Text] [Related]  

  • 7. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
    Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
    Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
    Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H
    Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry.
    Thidemann Andersen K; Klausen T; Abildgaard N; Klarskov Andersen M; Frost Andersen N; Christian Frølund U; Helleberg C; Kjeldsen E; Pedersen P; Helm-Petersen S; Svirskaite A; Preiss B; Gimsing P; Juul Vangsted A
    Am J Hematol; 2017 Oct; 92(10):E611-E614. PubMed ID: 28707398
    [No Abstract]   [Full Text] [Related]  

  • 10. Stable renal engraftment in a patient following successful tandem autologous/reduced-intensity conditioning allogeneic transplantation for treatment of multiple myeloma with del(17p) that developed as a post-transplantation lymphoproliferative disease following renal transplantation.
    Aoki T; Kasai M; Harada Y; Matsubara E; Morishita T; Suzuki T; Tsujita M; Goto N; Katayama A; Watarai Y; Uchida K; Ito M; Saji H; Tsuzuki T; Uchida T; Ogura M
    Int J Hematol; 2013 Jul; 98(1):129-34. PubMed ID: 23666631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion.
    Kitamura H; Kubota Y; Yamaguchi K; Kamachi K; Nishioka A; Yokoo M; Shindo T; Ando T; Kojima K; Kimura S
    Intern Med; 2018 Mar; 57(6):855-860. PubMed ID: 29151530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
    Cohen YC; Saranga A; Gatt ME; Lavi N; Ganzel C; Magen H; Avivi I; Tadmor T; Suriu C; Jarchowsky Dolberg O; Papushado A; Trestman S; Ram R
    Am J Hematol; 2018 Jun; 93(6):810-815. PubMed ID: 29603773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).
    Eom HS; Kim YK; Chung JS; Kim K; Kim HJ; Kim HY; Jin JY; Do YR; Oh SJ; Suh C; Seong CM; Kim CS; Lee DS; Lee JH
    Ann Hematol; 2010 May; 89(5):489-97. PubMed ID: 20012045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous stem cell transplantation in the treatment of multiple myeloma with 17p deletion.
    Czyż J; Jurczyszyn A; Szudy-Szczyrek A; Koclęga A; Jachalska A; Dzierżak-Mietła M; Puła B; Jamroziak K; Usnarska-Zubkiewicz L; Gil L; Romejko-Jarosińska J; Waszczuk-Gajda A
    Pol Arch Intern Med; 2020 Feb; 130(2):106-111. PubMed ID: 31933484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of consolidation therapy in transplant eligible multiple myeloma patients.
    Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E
    Semin Oncol; 2013 Oct; 40(5):610-7. PubMed ID: 24135406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of chromosomal aberrations in multiple myeloma.
    Nahi H; Sutlu T; Jansson M; Alici E; Gahrton G
    J Intern Med; 2011 Feb; 269(2):137-47. PubMed ID: 21158983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloma: management of the newly diagnosed high-risk patient.
    Dispenzieri A
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):485-494. PubMed ID: 27913520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
    Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.